We describe the development of a chromosome walking experiment using different strategies toward cloning a Cassava Mosaic Disease (CMD) resistance gene (CMD2). The first part of our project was the fine mapping of a population made up of 1690 individuals from a cross between TME-3, the source of CMD2 and the improved variety TMS30572. Two SSR markers previously reported NS158 and SSRY 28 were evaluated in the fine-mapping population and 112 recombinant individuals were identified. Two bulks from resistance and
